动静脉透析通路介入研究的定义与终点
本文为美国肾脏病学会肾脏健康倡议透析血管通路临床试验终点项目的一部分,聚焦动静脉通路。文章将通路生命周期分为五个阶段,前三个阶段分别定义为通畅、生理成熟和临床功能,并据此提出各阶段适用的临床试验终点,以支持临床、监管和报销决策。
要点
- 动静脉通路生命周期分为五个阶段,前三个阶段为通畅、生理成熟和临床功能。
- 各阶段有客观直接或间接标准,临床试验终点应与阶段对应。
- 使用统一定义和终点可使试验更贴合干预目标并支持决策。
核心结论
- 通过明确动静脉通路各阶段的定义和终点,可设计更贴合干预目标的临床试验,并为临床、监管和报销决策提供支持数据。
研究设计与样本
- 本文为美国肾脏病学会肾脏健康倡议透析血管通路临床试验终点项目的一部分,聚焦动静脉通路。
主要发现
- 动静脉通路生命周期分为五个阶段,前三个阶段为通畅、生理成熟和临床功能。
- 第四阶段为持续临床使用,第五阶段为功能障碍,两者可相互转换。
- 从持续临床使用阶段起,通路需要维护操作以保持或恢复持续临床使用。
关键数值与推荐
- 阶段1为通畅的动静脉通路。
- 阶段2为生理成熟的动静脉通路。
- 阶段3为临床功能的动静脉通路。
临床怎么用
- 临床试验设计时应根据动静脉通路所处阶段选择相应的终点。
- 使用统一定义和终点有助于将试验结果与干预目标对齐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This paper is part of the Clinical Trial Endpoints for Dialysis Vascular Access Project of the American Society of Nephrology Kidney Health Initiative. The purpose of this project is to promote research in vascular access by clarifying trial end points which would be best suited to inform decisions in those situations in which supportive clinical data are required. The focus of a portion of the project is directed toward arteriovenous access. There is a potential for interventional studies to be directed toward any of the events that may be associated with an arteriovenous access' evolution throughout its life cycle, which has been divided into five distinct phases. Each one of these has the potential for relatively unique problems. The first three of these correspond to three distinct stages of arteriovenous access development, each one of which has been characterized by objective direct and/or indirect criteria. These are characterized as: stage 1-patent arteriovenous access, stage 2-physiologically mature arteriovenous access, and stage 3-clinically functional arteriovenous access. Once the requirements of a stage 3-clinically functional arteriovenous access have been met, the fourth phase of its life cycle begins. This is the phase of sustained clinical use from which the arteriovenous access may move back and forth between it and the fifth phase, dysfunction. From this phase of its life cycle, the arteriovenous access requires a maintenance procedure to preserve or restore sustained clinical use. Using these definitions, clinical trial end points appropriate to the various phases that characterize the evolution of the arteriovenous access life cycle have been identified. It is anticipated that by using these definitions and potential end points, clinical trials can be designed that more closely correlate with the goals of the intervention and provide appropriate supportive data for clinical, regulatory, and coverage decisions.
引用
- Beathard GA, Lok CE, Glickman MH, et al. Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access. Clin J Am Soc Nephrol. 2017. PMID: 28729383. doi:10.2215/CJN.11531116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。